Author: Sheila Carney
Sheila Carney is co-lead director of our London studio. She plays a pivotal role in expanding STW’s presence in the UK market.
Proton beam therapy is a form of radiotherapy used to treat cancer which can be targeted extremely precisely, causing minimal damage to surrounding tissue. Proton beam therapy has been offered overseas to NHS patients who are eligible for treatment in England since 2008 in a programme that has to date supported approximately 1,000 patients. Together with the Department of Health, NHS England is funding the development of two world class centres at The Christie in Manchester and UCLH (University College London Hospitals NHS Foundation Trust) for NHS patients to be treated in the UK. Patients are due to be treated at The Christie from summer next year, with UCLH following in summer 2020. When complete they will each treat up to 750 patients every year. Dr Yen-Ch’ing Chang, clinical oncology consultant at UCLH and lead for proton beam therapy, says: "For certain cancers, conventional radiotherapy is the most suitable treatment. But when we are treating complex cancers, for instance in the brain, spine or near reproductive organs, and particularly in children, teenagers and young people, PBT has some advantages.
The physical properties of protons reduces damage to surrounding normal tissues. This protects, for instance, fertility, IQ or growth and reduces the risks of developing a new cancer in the future due to radiation treatment or the need for life long hormone replacements. It is extremely exciting that UCLH with The Christie is increasing access to this type of radiotherapy.” Marcel Levi, CEO of UCLH, said: “It is a tremendous privilege to develop a clinical facility that will truly change people’s lives. Here we will be able to treat more adults and children with proton beam therapy, ensuring better recovery and fewer side effects than possible with other treatments.” Fabienne Viala, Chairman of Bouygues UK, said: “This is exactly the kind of project we relish.
The complexity of undertaking London’s biggest excavation within a tight site at the heart of central London enables us to add value through our technical knowledge and the infrastructure expertise of our colleagues within Bouygues Travaux Publics. This is no ordinary project: as well as being an innovative and complex build, the finished development will have the potential to improve and even save the lives of those suffering with blood disorders and complex cancers.”
The low down: